Pfizer-BioNTech
Pfizer is Testing a Pill That Could Prevent COVID-19
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit “Cookie Settings” to provide a controlled consent. You Deserve to Make Money Even When you are looking for Dates Online. So we reimagined what a dating should be. It begins with giving you back power. Get to meet Beautiful people, chat and make money in the process. Earn rewards by chatting, sharing photos, blogging and help give users back their fair share of Internet revenue.
Moderna starts human trials of an mRNA-based flu shot
Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy. Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against. The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTec...
AstraZeneca: ‘No evidence’ of higher blood clots risk from coronavirus vaccine
UK-based pharmaceutical company AstraZeneca insisted on Friday its coronavirus vaccine was safe after some countries suspended its use in response to concerns about a potential link to blood clots. “An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country” from the jab, a company spokesperson said. “In fact, the observed number of these types of events are significantly lower in those vaccinated than would be expected among the general population.” The AstraZeneca jab, developed with Oxford University, forms the mainstay of Britain’s vaccination programme, and of many developing economies. It is relatively cheap and easier to st...
Israel, Bahrain leaders discuss Iran, possible vaccine plant
Israeli Prime Minister Benjamin Netanyahu and Bahrain’s Crown Prince Sheikh Salman bin Hamad Al Khalifa on Thursday discussed Iran and the possible involvement of the Gulf state in establishing a vaccine plant in Israel, the two countries said. Bahrain and the United Arab Emirates formalised ties with Israel on Sept. 15 in part over shared concerns about Iran, in a deal forged by former U.S. President Donald Trump. Trump withdrew from a 2015 nuclear deal between Tehran and world powers, a move praised by Israel which has objected to the accord. His successor, President Joe Biden, wants to rejoin the deal. But in the week since Washington offered to talk with Tehran about reviving the nuclear deal, Iran has curbed U.N. monitoring and threatened to boost its uranium enrichment. Tehran denies...
Pfizer, BioNTech to limit delays of vaccine shipments to one week
Pfizer and BioNTech said Saturday they will limit the delays of their vaccine deliveries to just one week, after fears in Europe that shipments of the jabs could be slowed for up to a month. The US drugmaker and its German partner “have developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the second quarter,” they said in a joint statement. “As a result, our facility in Puurs, Belgium will experience a temporary reduction in the number of doses delivered in the upcoming week.” Pfizer and BioNTech pledged that deliveries would be back to the original schedule to the European Union from the week of January 25, with increased delivery from the week of February 15. “To accomplish this, certain modifications of production pr...
Jordan detects two coronavirus variant cases – minister
Jordan on Sunday confirmed two cases of a particularly infectious coronavirus variant in a man and his wife who had arrived from Britain. Health Minister Nazir Obeidat said the Jordanian couple travelled to the kingdom on December 19 and were found to be infected with the new strain of the virus after being tested and isolated. The couple were still in quarantine and being monitored by medical experts according to virus protocols, Obeidat said, adding they were both in “excellent health” condition. The new strain of the virus emerged earlier this month in Britain and has already reached several European countries, as well as Japan and Canada. The new strain, which experts fear is more contagious, prompted more than 50 countries to impose travel restrictions on Britain. Jordan was among the...
Canada approves Pfizer-BioNTech coronavirus vaccine
Canadian health officials have authorised the Pfizer-BioNTech COVID-19 vaccine, hailing the development as a “critical milestone” and paving the way for the inoculant to be administered across the country. The authorisation on Wednesday comes a day after the United Kingdom became the first country to begin giving the vaccine to the public. Emergency use authorisation (EUA) is also pending in the United States, with officials saying the first doses could be administered as early as next week. The US Food and Drug Administration is scheduled to consider its EUA on Thursday. Bahrain has also authorised the vaccine for public use. “Canadians can feel confident that the review process was rigorous and that we have strong monitoring systems in place,” Health Canada, the department responsible fo...
Coronavirus vaccine breakthrough raises hopes of rapid global rollout
A coronavirus vaccine developed by Britain’s University of Oxford and the pharmaceutical firm AstraZeneca has shown successful results in early trials. If it is approved by regulators, the vaccine appears suitable for a fast rollout around the globe. Early analysis of trials involving 20,000 volunteers in Britain and Brazil show the vaccine is at least 62% effective after two doses. In volunteers given a different dosing regimen — a half dose, followed by a full dose — that figure rose to 90%. The average efficacy of the two dosing methods is 70%. None of those given the vaccine developed severe COVID-19 illness. Andrew Pollard, director of the Oxford Vaccine Group, said the recent successful trials of three different vaccines by Oxford-AstraZeneca, Pfizer-BioNTech and Moderna, represent a...
